A proposed Treasury rule has caused disagreement in the biopharma industry, according to STAT. The dispute centres on an exemption for a common type of transaction involving China, which some firms argue could affect their business models and partnerships.
This matters for pharma and biotech executives, as regulatory changes may alter the risk profile of cross-border deals and impact drug development timelines. Firms should review their exposure to affected deal types and prepare for possible adjustments if the rule is finalised.
